EV Therapeutics

EV Therapeutics is a San Diego-based biotech startup founded in 2018, pioneering a novel extracellular vesicle (EV) platform for cancer immunotherapy. The company's core technology involves engineering tumor-derived EVs to deliver immune-stimulating neoantigens while removing immunosuppressive factors, aiming to convert 'cold' tumors responsive to treatment, especially in combination with checkpoint blockade. Initially targeting the high-unmet-need metastatic colorectal cancer market, where most patients have microsatellite stable (MSS) tumors resistant to current immunotherapies, the company is in pre-clinical development with its lead candidate EV101.

Proprietary platform for engineering modified tumor extracellular vesicles (mTEVs). The platform isolates EVs from tumor cells, modifies them to carry immune-stimulating neoantigens while removing immunosuppressive factors, creating an off-the-shelf therapeutic vaccine designed to activate T cells and convert immunologically 'cold' tumors to 'hot'.

EV Therapeutics operates in the competitive and rapidly evolving fields of exosome/EV therapeutics and cancer vaccines. It faces competition from other biotechs developing EV-based delivery systems and from companies pursuing alternative modalities (e.g., oncolytic viruses, cell therapies, other vaccine platforms) to sensitize cold tumors to immunotherapy.